Enters into a definite agreement with Mylan Inc to sell-off Agila Specialties division for a cash consideration of USD 1.6 billion and potential additional consideration of USD 250 million.
Consolidated stake in Inbiopro Solutions Pvt. Ltd. from initial holdings of 70% to 100% to become a 100% subsidiary of Strides.
Agila Biotech entered into a JV with Pfenex Inc. CA, USA to develop, manufacture and commercialize an initial pipeline of 6 bio-similars.
Strides sells its generic pharmaceuticals operations in Australia & SE Asia (Ascent) to Watson Pharmaceuticals for AUD 375 million.
Specialties Division, Agila, acquired an USFDA approved sterile formulations facility in Hosur, Tamilnadu, India from Star Drugs for Rs.1250 million.
Entered Canadian sterile space through a marketing JV with Jamp Pharma, a Canadian generic drug company.
Collaborations with GILEAD Sciences Inc. to promote access to high-quality, low-cost generic versions of their HIV medicines in developing markets.
Filed 31 ANDAs during the year and received 27 approvals taking total ANDA filings to 183 and total approvals to 79.
Launched Vancomycin in the US through JV partner and later through Pfizer mitigating drug shortage.
Revenues from Specialties business grew 48% to cross Rs.1000 crores in 2011.
Entered into collaboration with Pfizer to license and supply 40 off-patent products, largely oncology products, for the US market; bought Campos facility in Brazil from Aspen
Extended Pfizer transaction to cover Canada, Australia, European Union, Japan, New Zealand and Korea
Rebranded Specialty Division as Agila Specialties Private Limited
Acquired biotechnology company Inbiopro Solutions to enter the biologics space
Launched Ray of Life, a critical care division with a portfolio of specialty products addressing the hospital segment in India
Launched Starflu to treat H1N1
Restructured business divisions into Pharma (Pharma Generics and Branded Generics) and Specialty
Entered into a significant licensing deal with GlaxoSmithKline Pharmaceuticals for distribution in over 95 countries
Acquired controlling stake in Ascent PharmaHealth, an AXS listed Company and a major generics player in Australia
Formed a joint venture with Sagent Pharmaceuticals for specialty products in USA
Acquired Grandix, a leading brand marketing company, to enter the Indian domestic market; bought out stake and acquired 100% ownership of Farma Plus AS in Norway
Ceded 50% ownership in LATAM operations to Aspen Group
Formed a joint venture with Aspen Group to set up an Oncology facility in India
Entered into an alliance with the Clinton Foundation for supplying AIDS drugs; acquired ICN Valeant Sterile's manufacturing unit in Poland; acquired a controlling stake in Beltapharm SpA in Italy; acquired Drug Houses of Australia (Asia) Pte Limited, Singapore; entered into a joint venture with Invent Farma in Spain to market products in the Spanish and Portuguese markets
Inaugurated the global research and development centre, Star Technology and Research or STAR, at Bangalore
Entered into a joint venture with Akorn Inc., USA to penetrate the US hospital market for sterile products
Commenced development and manufacture of drugs against AIDS, TB and Malaria
Company listed on the Bombay Stock Exchange
Acquired a stake in Solara, Mexico and set up manufacturing plants in Brazil and Mexico
Bombay Drugs & Pharmaceuticals merged into Strides Arcolab
Acquired Bombay Drugs & Pharmas Limited which has manufacturing facilities in Tarapur, Maharashtra and Panoli, Gujarat
Company listed on the National Stock Exchange (NSE)
Acquired Strides soft gelatin facility in the USA
Entered LATAM market through investments in Infabra, Brazil
Acquired Remed Laboratories
Acquired Global Remedies Limited, a manufacturing plant at Hosur, Tamil Nadu
Plama Laboratories and Remed Laboratories merged into Strides Arcolab
Acquired Plama Laboratories Limited, a bulk drug facility in Mangalore
Company name changed to Strides Arcolab Limited
New sterile manufacturing facility in Bangalore commenced production
Established soft gelatin capsule plant in India
Venture capital funding received from Schroders
Exports to Nigeria commenced
Strides Pharmaceuticals Private Limited, a first generation company established in Vashi, New Bombay